How to Get Provigil (Modafinil) in Nevada

What Modafinil Is and Why It Requires a Prescription

Modafinil is a wakefulness-promoting agent classified as a Schedule IV controlled substance under the DEA. The FDA first approved modafinil in 1998 for the treatment of excessive daytime sleepiness associated with narcolepsy, based on data from two key multicenter trials. In the US Modafinil in Narcolepsy Multicenter Study Group trial, modafinil 200 mg and 400 mg both significantly reduced excessive daytime sleepiness on the Epworth Sleepiness Scale compared to placebo (P<0.001 for both doses) [1]. A later randomized trial published in the Annals of Internal Medicine confirmed modafinil's efficacy for shift-work sleep disorder, with 74% of modafinil-treated patients showing clinical improvement versus 36% on placebo [2].

Because modafinil carries abuse potential (albeit lower than amphetamine-class stimulants), the DEA schedules it at Schedule IV, meaning every dispense requires a valid prescription from a licensed provider. Nevada follows federal scheduling without additional state-level restrictions on modafinil prescribing. The Provigil prescribing information lists recommended dosing at 200 mg taken once in the morning for narcolepsy and OSA, or approximately one hour before the start of a work shift for shift-work disorder.

Who Can Prescribe Provigil in Nevada

Any Nevada-licensed prescriber with DEA authority to prescribe Schedule IV substances can write a modafinil prescription. This includes physicians (MD/DO), nurse practitioners, and physician assistants.

Nevada NPs gained full practice authority in 2021 under SB 232, removing the prior collaborative agreement requirement after completing a minimum transition-to-practice period. NPs who have satisfied this requirement can independently prescribe Schedule II through V controlled substances [3]. Physician assistants in Nevada must maintain a collaborative agreement with a supervising physician but can prescribe Schedule IV drugs including modafinil under that agreement, per NRS 630.271.

Sleep specialists and neurologists most commonly initiate modafinil for narcolepsy. Primary care providers, including family medicine and internal medicine physicians, frequently prescribe it for shift-work disorder. The American Academy of Sleep Medicine clinical practice guideline lists modafinil as a first-line pharmacologic treatment for excessive daytime sleepiness in narcolepsy type 2, noting strong evidence and a favorable side-effect profile compared to traditional stimulants [4].

Telehealth Prescribing of Modafinil in Nevada

Nevada permits telehealth prescribing of Schedule IV controlled substances. This is a direct pathway for residents who lack geographic access to a sleep medicine specialist.

The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one valid evaluation before a controlled substance can be prescribed via telemedicine. Nevada telehealth statutes, codified under NRS 629.515, align with this federal standard. A provider must conduct a synchronous audio-video consultation, document the medical history, and establish a provider-patient relationship before issuing a Schedule IV prescription. The DEA's telemedicine flexibilities extended under the 2024 final rule allow the initial evaluation to occur via telehealth for Schedule III through V substances without requiring a prior in-person visit, provided the prescriber holds a DEA registration in the state where the patient is located.

A typical telehealth workflow for modafinil in Nevada involves intake screening, a 15 to 25 minute synchronous video consultation, medical record review, and e-prescribing directly to the patient's chosen pharmacy. Most telehealth platforms can complete this process within 1 to 3 business days.

What Labs and Evaluations Are Needed Before Starting Modafinil

Prescribers in Nevada generally require baseline labs and a clinical sleep evaluation before initiating modafinil.

A polysomnogram (PSG) followed by a Multiple Sleep Latency Test (MSLT) is the diagnostic standard for narcolepsy. The AASM scoring manual defines narcolepsy type 1 by a mean sleep latency of <8 minutes with two or more sleep-onset REM periods, combined with cataplexy or low CSF hypocretin-1 [5]. For shift-work disorder, the International Classification of Sleep Disorders, 3rd edition requires insomnia or excessive sleepiness temporally associated with a recurring work schedule that overlaps the habitual sleep period [6].

Baseline labs are not universally mandated by the FDA label, but most prescribers order:

• Comprehensive metabolic panel (CMP) to assess hepatic function, since modafinil is extensively metabolized by CYP3A4 in the liver
• Complete blood count (CBC) as a general health screen
• Thyroid-stimulating hormone (TSH) to rule out hypothyroidism as a cause of excessive daytime sleepiness
• Urine drug screen, sometimes requested to rule out concurrent stimulant use

The Provigil prescribing information specifically warns against use in patients with a history of left ventricular hypertrophy or cor pulmonale, recommending cardiovascular evaluation in patients with mitral valve prolapse or recent cardiac symptoms [7]. A resting ECG may be ordered at provider discretion.

Nevada Medicaid Does Not Cover Provigil

Nevada Medicaid does not include modafinil on its preferred drug list. Patients relying on Medicaid in Nevada will face a full out-of-pocket cost for both brand and generic formulations.

Generic modafinil 200 mg tablets typically cost between $30 and $60 for a 30-day supply at retail pharmacies in Nevada, based on GoodRx cash-price data. Brand-name Provigil can exceed $900 per month without insurance. The Centers for Medicare and Medicaid Services allows individual state Medicaid programs to establish their own formularies for non-protected drug classes, and Nevada has exercised this authority by excluding wakefulness-promoting agents from coverage.

Commercial insurers in Nevada (including plans through the Silver State Health Insurance Exchange) do cover modafinil, but almost universally require prior authorization. A 2022 systematic review in the Journal of Managed Care & Specialty Pharmacy found that 78% of commercial plans required PA for modafinil, with the most common criteria being a confirmed diagnosis of narcolepsy or OSA with documented CPAP use [8]. Step therapy requiring a trial of generic modafinil before brand Provigil is standard.

What Prior Authorization Requires in Nevada

Prior authorization for modafinil through a Nevada commercial plan typically requires three categories of documentation.

First, a confirmed sleep disorder diagnosis. Insurers expect ICD-10 codes (G47.411 for narcolepsy type 1, G47.419 for narcolepsy type 2, G47.26 for shift-work disorder) supported by clinical documentation. For narcolepsy, this means PSG/MSLT results. For OSA-related excessive sleepiness, the insurer typically requires evidence of CPAP compliance, defined as at least 4 hours per night on 70% of nights over a 30-day period per CMS criteria. The AASM position statement on PAP therapy adherence uses this same 70% threshold [9].

Second, prescriber credentials and a treatment rationale. The PA form asks for the prescriber's NPI, DEA number, and a brief clinical justification explaining why modafinil is medically necessary.

Third, failure of conservative measures or contraindication to alternatives. Some plans require documentation that behavioral sleep hygiene interventions were attempted, or that the patient cannot tolerate first-line agents. This requirement varies by insurer. UnitedHealthcare Nevada plans, for example, require only a confirmed diagnosis and a provider attestation for generic modafinil, while brand-name Provigil requires both step therapy failure and PA.

Turnaround for PA decisions in Nevada is governed by NAC 687B.665, which requires insurers to respond within 5 business days for non-urgent requests and within 72 hours for urgent requests.

503A Compounding Pharmacies and Modafinil in Nevada

Nevada licenses 503A compounding pharmacies through the Nevada State Board of Pharmacy. These pharmacies can compound modafinil into alternative dosage forms (such as suspensions or capsules with modified doses) when a prescriber writes a patient-specific prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act exempts compounded drugs from certain FDA requirements when they are prepared by a licensed pharmacist based on a valid individual prescription. In Nevada, 503A pharmacies must comply with USP 795 standards for nonsterile compounding and USP 797 for sterile preparations [10].

For modafinil specifically, 503A compounding is relevant when patients need doses not commercially available (such as 50 mg or 150 mg), when they cannot swallow tablets, or when they require a formulation free of specific excipients due to allergies. The pharmacy must source modafinil active pharmaceutical ingredient (API) from an FDA-registered supplier and maintain batch records.

Nevada residents can also receive compounded modafinil shipped from out-of-state 503A pharmacies, provided the sending pharmacy holds a Nevada nonresident pharmacy license from the Board. The Nevada Pharmacy Practice Act, NRS 639 requires nonresident pharmacies to register and maintain equivalent quality standards.

How Long Until You Receive Modafinil in Nevada

Turnaround depends on the prescribing pathway and pharmacy type.

For in-person visits, a prescription sent electronically to a retail pharmacy (CVS, Walgreens, Smith's) is typically filled same-day or next business day if the drug is in stock. Generic modafinil is widely stocked at Nevada retail pharmacies. Brand-name Provigil may require a special order, adding 1 to 2 business days.

For telehealth visits, the process from initial consultation to prescription pickup averages 1 to 5 business days. The consultation itself can occur within 24 to 48 hours on most platforms. E-prescribing to the pharmacy is immediate after the visit.

When prior authorization is required, the PA review adds 1 to 5 business days for standard requests. An expedited PA request under Nevada insurance regulations must be decided within 72 hours if the prescriber attests that delay could seriously jeopardize the patient's health.

503A compounding pharmacies require longer. Custom formulations typically take 3 to 7 business days to prepare, plus shipping time if using an out-of-state compounder. Patients should plan for 5 to 10 business days total from prescription to delivery for compounded modafinil.

Transferring a Modafinil Prescription to Nevada

Patients relocating to Nevada or traveling within the state can transfer an existing modafinil prescription from an out-of-state pharmacy to a Nevada pharmacy. Federal law permits the transfer of Schedule IV prescriptions, and the DEA clarified in its 2023 rulemaking that electronic prescription transfers between pharmacies are valid for Schedule III through V drugs.

Nevada law, under NRS 639.2353, permits one transfer of a Schedule III through V prescription between pharmacies. The receiving pharmacist must verify the prescription with the originating pharmacy and document the transfer, including the originating pharmacy's DEA number and the number of remaining refills.

Patients should note that modafinil prescriptions are typically written for a maximum of 6 months of refills. If the original prescription has expired or has no remaining refills, a new prescription from a Nevada-licensed provider is required.

Safety Considerations Specific to Modafinil

Modafinil's side-effect profile is well-characterized across decades of post-market surveillance. The most common adverse events in clinical trials were headache (34% vs. 23% placebo), nausea (11% vs. 3% placebo), and nervousness (7% vs. 3% placebo), as documented in the Provigil FDA label [7].

Serious but rare adverse events include Stevens-Johnson syndrome and toxic epidermal necrolysis. The FDA issued a safety communication in 2007 recommending immediate discontinuation at the first sign of rash [11]. A retrospective cohort analysis published in Drug Safety (2018) estimated the incidence of SJS/TEN with modafinil at approximately 1 to 6 cases per million users [12].

Modafinil is a moderate CYP3A4 inducer and a CYP2C19 inhibitor, which affects the metabolism of hormonal contraceptives, warfarin, and cyclosporine [13]. Women using oral contraceptives should use an alternative or supplemental contraceptive method during modafinil therapy and for one month after discontinuation, per the FDA label. A pharmacokinetic study in the British Journal of Clinical Pharmacology confirmed that modafinil reduced ethinyl estradiol AUC by 18% at steady state [14].

Nevada prescribers should screen for a personal or family history of angioedema or hypersensitivity to armodafinil (Nuvigil), as cross-reactivity has been reported. Patients with hepatic impairment (Child-Pugh B or C) require dose reduction to 100 mg daily, as modafinil clearance decreases by approximately 60% in moderate hepatic impairment [7].

Off-Label Cognitive Enhancement and Nevada Law

Some Nevada patients seek modafinil for off-label cognitive enhancement rather than an FDA-approved indication. Off-label prescribing is legal in the United States and protected under the physician's scope of practice. A meta-analysis in European Neuropsychopharmacology reviewed 24 studies and found that modafinil improved attention, executive function, and learning in non-sleep-deprived individuals, with a favorable safety profile in short-term use [15].

Nevada has no state-specific prohibition on off-label prescribing of modafinil. Insurance coverage for off-label use is unlikely. Patients seeking modafinil for cognitive enhancement should expect to pay cash prices, and prescribers should document the clinical rationale thoroughly.

The starting dose for off-label cognitive use is typically 100 mg once in the morning, titrated to 200 mg based on response and tolerability. A dose-response study in Psychopharmacology found that 200 mg produced maximal cognitive benefit in healthy volunteers, with no additional gain at 400 mg [16].